Journal
CANCERS
Volume 13, Issue 2, Pages -Publisher
MDPI
DOI: 10.3390/cancers13020287
Keywords
antibody therapy; immuno-oncology; CD3-bispecific antibody; T-cell engager; solid tumors; on-target off-tumor toxicity; T-cell co-stimulation; tumor-associated antigens
Categories
Funding
- Genmab
Ask authors/readers for more resources
CD3-bispecific antibody therapy is a rapidly developing field in immunotherapy, with approved use in hematological malignancies and ongoing research in solid tumors. However, treatment of solid tumors faces more challenges, including increased on-target off-tumor toxicities, sparse T-cell infiltration, and impaired T-cell quality due to an immunosuppressive tumor microenvironment, affecting the safety and efficacy of CD3-bispecific antibody therapy. Various combinatorial approaches are being explored to overcome these hurdles and improve the selectivity and effectiveness of the therapy.
Simple Summary CD3-bispecific antibody therapy is a form of immunotherapy that enables soldier cells of the immune system to recognize and kill tumor cells. This type of therapy is currently successfully used in the clinic to treat tumors in the blood and is under investigation for tumors in our organs. The treatment of these solid tumors faces more pronounced hurdles, which affect the safety and efficacy of CD3-bispecific antibody therapy. In this review, we provide a brief status update of this field and identify intrinsic hurdles for solid cancers. Furthermore, we describe potential solutions and combinatorial approaches to overcome these challenges in order to generate safer and more effective therapies. Immunotherapy of cancer with CD3-bispecific antibodies is an approved therapeutic option for some hematological malignancies and is under clinical investigation for solid cancers. However, the treatment of solid tumors faces more pronounced hurdles, such as increased on-target off-tumor toxicities, sparse T-cell infiltration and impaired T-cell quality due to the presence of an immunosuppressive tumor microenvironment, which affect the safety and limit efficacy of CD3-bispecific antibody therapy. In this review, we provide a brief status update of the CD3-bispecific antibody therapy field and identify intrinsic hurdles in solid cancers. Furthermore, we describe potential combinatorial approaches to overcome these challenges in order to generate selective and more effective responses.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available